Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1991 Apr;72(4):584–587.

Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2.

Y Zaloom 1, L P Walsh 1, P McCulloch 1, G Gallagher 1
PMCID: PMC1384382  PMID: 2037319

Abstract

The immunopharmacological effects of interleukin-2 (IL-2) on the sensitization and effector phases of the delayed-type hypersensitivity (DTH) reaction were studied using contact sensitivity to the haptenizing agent dinitrochlorobenzene (DNCB). When administered at the time of priming to DNCB, IL-2 had no effect on the subsequent magnitude of the response. Interleukin-2 was, however, able to increase the magnitude of the response when given at the time of secondary challenge; the degree of change was directly related to the dose of IL-2. The proportions of T cells in the draining lymph node and spleen of IL-2-treated animals decreased by approximately one-third, but there was no alteration to the balance between CD4+ and CD8+ T cells. The results suggest that the increase in DTH observed was due to a pharmacological effect rather than to an increase in T-cell number.

Full text

PDF
585

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cherwinski H. M., Schumacher J. H., Brown K. D., Mosmann T. R. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987 Nov 1;166(5):1229–1244. doi: 10.1084/jem.166.5.1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Donohue J. H., Lotze M. T., Robb R. J., Rosenstein M., Braziel R. M., Jaffe E. S., Rosenberg S. A. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res. 1984 Apr;44(4):1380–1386. [PubMed] [Google Scholar]
  3. Emery P., Panayi G. S., Nouri A. M. Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol. 1984 Jul;57(1):123–129. [PMC free article] [PubMed] [Google Scholar]
  4. Essery G., Feldmann M., Lamb J. R. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology. 1988 Jul;64(3):413–417. [PMC free article] [PubMed] [Google Scholar]
  5. Ettinghausen S. E., Lipford E. H., 3rd, Mulé J. J., Rosenberg S. A. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol. 1985 Aug;135(2):1488–1497. [PubMed] [Google Scholar]
  6. Haregewoin A., Godal T., Mustafa A. S., Belehu A., Yemaneberhan T. T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Nature. 1983 May 26;303(5915):342–344. doi: 10.1038/303342a0. [DOI] [PubMed] [Google Scholar]
  7. Kaplan G., Kiessling R., Teklemariam S., Hancock G., Sheftel G., Job C. K., Converse P., Ottenhoff T. H., Becx-Bleumink M., Dietz M. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med. 1989 Mar 1;169(3):893–907. doi: 10.1084/jem.169.3.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kern D. E., Gillis S., Okada M., Henney C. S. The role of interleukin-2 (IL-2) in the differentiatin of cytotoxic T cells: the effect of monoclonal anti-IL-2 antibody and absorption with IL-2 dependent T cell lines. J Immunol. 1981 Oct;127(4):1323–1328. [PubMed] [Google Scholar]
  9. Kornfeld H., Berman J. S., Beer D. J., Center D. M. Induction of human T lymphocyte motility by interleukin 2. J Immunol. 1985 Jun;134(6):3887–3890. [PubMed] [Google Scholar]
  10. Lamb J. R., Skidmore B. J., Green N., Chiller J. M., Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med. 1983 May 1;157(5):1434–1447. doi: 10.1084/jem.157.5.1434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lotze M. T., Finn O. J. Recent advances in cellular immunology: implications for immunity to cancer. Immunol Today. 1990 Jun;11(6):190–193. doi: 10.1016/0167-5699(90)90079-o. [DOI] [PubMed] [Google Scholar]
  12. Lotze M. T., Matory Y. L., Ettinghausen S. E., Rayner A. A., Sharrow S. O., Seipp C. A., Custer M. C., Rosenberg S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985 Oct;135(4):2865–2875. [PubMed] [Google Scholar]
  13. Malkovský M., Loveland B., North M., Asherson G. L., Gao L., Ward P., Fiers W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987 Jan 15;325(6101):262–265. doi: 10.1038/325262a0. [DOI] [PubMed] [Google Scholar]
  14. Malkovský M., Medawar P. B., Thatcher D. R., Toy J., Hunt R., Rayfield L. S., Doré C. Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate. Proc Natl Acad Sci U S A. 1985 Jan;82(2):536–538. doi: 10.1073/pnas.82.2.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Morahan G., Allison J., Miller J. F. Tolerance of class I histocompatibility antigens expressed extrathymically. Nature. 1989 Jun 22;339(6226):622–624. doi: 10.1038/339622a0. [DOI] [PubMed] [Google Scholar]
  16. Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976 Sep 10;193(4257):1007–1008. doi: 10.1126/science.181845. [DOI] [PubMed] [Google Scholar]
  17. Mosmann T. R., Coffman R. L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol. 1989;46:111–147. doi: 10.1016/s0065-2776(08)60652-5. [DOI] [PubMed] [Google Scholar]
  18. Mulé J. J., Shu S., Rosenberg S. A. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol. 1985 Jul;135(1):646–652. [PubMed] [Google Scholar]
  19. Rosenberg S. A., Grimm E. A., McGrogan M., Doyle M., Kawasaki E., Koths K., Mark D. F. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30;223(4643):1412–1414. doi: 10.1126/science.6367046. [DOI] [PubMed] [Google Scholar]
  20. Rosenberg S. A., Spiess P. J., Schwarz S. In vivo administration of Interleukin-2 enhances specific alloimmune responses. Transplantation. 1983 Jun;35(6):631–634. doi: 10.1097/00007890-198306000-00024. [DOI] [PubMed] [Google Scholar]
  21. Thoman M. L., Weigle W. O. Cell-mediated immunity in aged mice: an underlying lesion in IL 2 synthesis. J Immunol. 1982 May;128(5):2358–2361. [PubMed] [Google Scholar]
  22. Turk J. L., Bryceson A. D. Immunological phenomena in leprosy and related diseases. Adv Immunol. 1971;13:209–266. doi: 10.1016/s0065-2776(08)60185-6. [DOI] [PubMed] [Google Scholar]
  23. Wang B. S., Heacock E. H., Zheng C. X., Tilney N. L., Mannick J. A. Restoration of allogeneic responsiveness of lymphocytes from cyclosporin A-treated animals with interleukin 2. Transplantation. 1982 Apr;33(4):454–456. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES